Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NK Cell Infusion for Advanced Malignant Tumors
NCT03619954Phase 1Unknown
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- Jul 2018
- Primary completion
- Jul 2019
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NK cell therapy (Anhui Provincial Hospital) in advanced malignant solid tumor and hematologic malignancy, sponsored by The First Affiliated Hospital of USTC. Primary endpoints: Successful expansion of NK cells in patient's circulatory system and Objective Response Rate. Status: unknown.
02
Drugs
NK cell therapy (Anhui Provincial Hospital)
03
Conditions
advanced malignant solid tumorhematologic malignancy
Beyond the preview
Go deeper on NCT03619954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03619954.